Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04369937
Title HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Robert Ferris
Indications

head and neck squamous cell carcinoma

Therapies

Cisplatin + ISA101b + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST